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Common variants in APOA5 and APOC3 have been associated with differences in plasma triglyceride (TG) levels in healthy individuals. The
aim of this study was to examine the association of APOA5 (−1131T>C, S19W) and APOC3 (−482C>T, 1100C>T) polymorphisms in patients
with type 2 diabetes (T2D) of European White (EW) (n=931), Indian Asian (IA) (n=610) and Afro-Caribbean (AC) (n=167) origin, with lipid
and T2D parameters. Rare allele frequencies and linkage disequilibrium differed significantly amongst ethnic groups. Compared to APOA5
−1131T and 19S homozygotes, −1131C and 19W carriers had higher TGs in all groups, but this effect was only statistically significant for the
−1131C in the EWs (P=0.04) and 19W in the IAs (P<0.001). APOC3 SNPs showed no significant association with lipid levels in any ethnic
group. While haplotypes carrying −1131C allele showed significant TG-raising in the EWs only, the 19W defined haplotype showed significant
TG-raising in both IAs and EWs. Comparing all four SNPs in EW T2D subjects with healthy EWs (n=2579), the APOC3 1100C>T frequency
was significantly higher in T2D [0.26 (0.24, 0.28)] vs. healthy EWs [0.22 (0.20, 0.23)], P=0.001. While the variable size effects of the two
APOA5 SNPs on TG levels may result from ethnically different gene–gene or gene–environment interactions, APOA5 and APOC3 variants
did not affect parameters of T2D. However, comparison between EWs with T2D and healthy EWs suggest APOC3 1100C>T is associated with
increased risk of diabetes probably through mechanisms other than direct effects on TG.
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Type 2 diabetes (T2D) is a global pandemic increasing and
already affecting over 150 million people worldwide [1]. There
is considerable ethnic variation in the prevalence, incidence and
disease progression with adult T2D being about three to five
times greater in Afro-Caribbeans (ACs) and South Asians
compared to European Whites (EWs) [2].
Heart disease is 3–5 times more common in T2D. Patients
have a typical atherogenic dyslipidemia profile characterised by⁎ Corresponding author. Centre for Cardiovascular Genetics, Department of
Medicine, British Heart Foundation Laboratories, Rayne Building, Royal Free
and University College London Medical School, 5 University Street, London
WC1E 6JF, UK.
E-mail address: b.dorfmeister@ucl.ac.uk (B. Dorfmeister).
0925-4439/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2006.11.008raised fasting triglyceride (TG) levels, excessive postprandial
lipaemia and low HDL cholesterol. Patients with T2D also tend
to have a preponderance of atherogenic small dense LDL [3].
Since raised TG levels are an independent risk factor for
cardiovascular disease [4], the genetic determinants of TGs
might play a part in the hypertriglyceridemia prevalent in T2D.
The APOA5/A4/C3/A1 gene cluster on chromosome 11 is of
interest, as common single nucleotide polymorphisms (SNPs) in
APOC3 and APOA5 have been associated with differences in
plasma TG levels in healthy individuals [5–8]. APOA5 is a
hepatically expressed minor constituent of HDL, which in the
postprandial state transfers to VLDL [9,10]. APOC3, a
component of TG-rich lipoproteins and HDL, is mainly
synthesized in the liver and to some extent in the intestine [11].
Linkage disequilibrium (LD) structure and haplotype patterns
between APOA5 and APOC3 have been studied [5,12–14]. Two
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defined by five SNPs, −1131T>C, −3A>G, IVS3+, 476G>A,
1259T>C andAPOA5*3, defined by the rare allele of the 56C>G
SNP (S19W) [6,7]. Thus,−1131T>C and S19Wessentially act as
tagging SNPs for these two TG-raising haplotypes. Haplotype
analysis of the chromosome 11 gene cluster suggests that while
S19Windependently affects TG levels [13] and has been shown to
be functional [15], APOA5*2 is significantly associated with the
rare alleles of the APOC3 Sst I (3238G>C) and the two promoter
SNPs, −482C>T and −455T>C [12], of which the −482C>T
has been shown to be functional [16].
Very few studies have looked at the relationship between
APOA5 [17–20] andAPOC3 gene polymorphisms and lipid traits
[19,21,22] in patients with T2D in different ethnic groups [20,23].
Since no data are available for the APOA5 S19W or APOC3
1100C>T variants in patients with T2D, the purpose of this study
was to examine the association of two APOA5 (−1131T>C and
S19W) and two APOC3 SNPs (−482C>T and 1100C>T) with
lipid traits, primarily TG levels, in European White (EW), Indian
Asian (IA) and Afro-Caribbean (AC) patients with T2D. These
effects in the EWs with T2D were also compared to healthy EWs
who had participated in the prospective Northwick Park Heart
Study II and in whom the effects of APOA5 [13] and APOC3 [8]
variants had been previously reported. Association with other
indicators of risk of T2Dwas also examined, namely age of onset,
duration of diabetes (calculated from reported age of diabetes
onset to age at entry into the study), and obesity as measured by
body mass index (BMI).
2. Materials and methods
2.1. Population studies
2.1.1. UCL diabetes and cardiovascular disease study; UDACS
This is a cross-sectional sample of subjects designed to study the association
between common variants in inflammatory/metabolic genes and biochemical
risk factors implicated in CHD in patients with diabetes [24,25]. Briefly, 1100
consecutive patients were recruited from the diabetes clinic at University CollegeTable 1
Baseline characteristic in UDACS and EDSC for patients with T2D and NPSHII
Baseline characteristics (T2D)
EWs
(N=587)
IAs
(N=354)
ACs
(N=108)
Male (%) 59.6 (554) 59.6 (361) 63.9 (106)
BMI (kg/m2)* 29.3 (5.5) 27.7 (4.5) 28.4 (4.9)
Age of onset diabetes (y) 54.6 (13.2) 47.8 (11.5) 50.8 (10.6)
Age of recruitment (y) 65.6 (12.1) 58.5 (11.5) 61.6 (11.2)
Duration of diabetes (y)+ 9 [4–15] 10 [5–16] 10 [5–15]
Chol (mmol/l) 5.01 (1.10) 4.91 (1.14) 4.99 (1.04)
HDL-Chol (mmol/l)* 1.24 (0.37) 1.14 (0.28) 1.40 (0.41)
TG (mmol/l)* 1.90 (1.10) 2.04 (1.06) 1.44 (0.77)
LDL-Chol (mmol/l)x 2.72 (0.92) 2.73 (0.93) 2.76 (0.92)
Glucose (mmol/l)+ 10.7 [7.9–14.6] 11.7 [8.6–15] 10.2 [7.4–14.
HbA1c (%) 8.03 (1.82) 8.66 (2.08) 8.40 (2.07)
SBP (mm Hg) 140.8 (20.1) 136.9 (20.7) 144.0 (20.9)
DBP (mm Hg) 77.3 (11.6) 76.0 (11.3) 79.5 (12.1)
Data is presented as ∗ geometric means±approximately standard deviation or +medLondon Hospitals NHS Trust in Central London between the years 2001 and
2002. Ethical approval was granted by the institutional ethics committee, and all
participants gave written informed consent before recruitment. Analyses were
confined to 781 patients with T2D (EWs n=600, IAs n=107 and ACs n=74).
2.1.2. Ealing diabetes study of coagulation; EDSC
Patients were recruited consecutively from a diabetes clinic at Ealing
Hospital in Central London at the same time as UDACS over a 2-year period
from 2001 (n=1270). Approval was given for the study from Ealing Hospital
Ethics Committee and all individuals gave written informed consent. The study
was designed to address genotype/phenotype associations (particularly in
haemostatic and anti-inflammatory pathways) in T2D and to identify risk factors
for CHD primarily in three ethnic groups, IAs, EWs and ACs [26]. Analysis was
restricted to patients with T2D (total of 927 patients, EWs n=331, IAs n=503
and ACs n=93). Biochemical, disease related and demographic results for each
patient, specific to the recruitment date, were retrieved from clinic.
UDACS and EDSC were recruited simultaneously from London hospitals
with a view to combining genetic analysis and all patients were diagnosed with
T2D using the same diagnostic criteria [27].
2.1.3. Northwick park heart study; NPHSII
NPHSII is a prospective study of healthy men aged 50–64 years at baseline,
who were clinically free of cardiovascular disease at that time. The cohort is well
documented in peer-reviewed literature [28,29]. The study commenced in 1989
and is based within nine general medical practices in England and Scotland. Of
4600 men, 4141 were eligible for study and 3052 were recruited. Blood was
taken in the non-fasting state for haemostatic factors and other biochemical
markers. In the current analysis, non-Caucasian subjects were excluded, as well
as 75 men, who were diabetic at baseline and 174 men, who developed diabetes
during follow up, leaving 2735 of whom 2350 individuals were successfully
genotyped, as published elsewhere [8,13]. Briefly, lipid characteristics were: TG
levels 1.76±0.92 mmol/l, total cholesterol levels 5.72±1.00 mmol/l, LDL levels
3.99±0.95 mmol/l and HDL levels 0.81±0.24 mmol/l and BMI were 26±
3.3 kg/m2 (mean±SD, Table 1).
In all three studies, UDACS, EDSC and NPHSII, non-fasting blood samples
were taken.
2.1.4. APOA5 genotyping
DNA was extracted using the salting out method [30]. The two APOA5
SNPs, −1131T>C and S19W, in the UDACS, EDSC and NPHSII studies were
assayed using PCR and restriction enzyme digest as previously reported [13]. In
the NPHSII study, APOC3 SNPs (−482C>T and 1100C>T) were assayed
using PCR and restriction enzyme digest as previously reported in [31]. APOC3
SNPs in the UDACS/EDSC samples were genotyped with Taqman (AppliedP value
EWs v IAs
P value
ACs v EWs
P value
ACs v IAs
NPHSII
(N=2578)
P value
EWs T2D v
NPHSII
0.79 0.48 0.96 100 (2578)
<0.001 0.004 0.005 26.0 (3.3) <0.001
<0.001 0.20 0.08 –
<0.001 0.002 <0.001 –
0.08 0.44 0.77 –
0.23 0.87 0.48 5.72 (1.00) <0.001
0.02 <0.001 <0.001 0.81 (0.24) <0.001
0.38 <0.001 <0.001 1.76 (0.92) <0.001
0.63 0.998 0.64 3.99 (0.95) <0.001
5] 0.15 0.03 0.12 –
0.10 0.17 0.42 –
0.74 0.17 0.42 137.8 (19.1) <0.001
0.42 0.003 0.006 84.5 (11.4) <0.001
ian (interquartile range).
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supplied on demand.
APOA5 −1131T>C (rs662799): AV_F: CCCTGCGAGTGGAGTTCA;
AV_R: CTCTGAGCCCCAGGAACTG, [FAM-AGCGAAAGTAA-
GATTT-NFQ]
APOA5 S19>W (rs3135506): AV_F: CCAGGCCCTGATTACCTAGTC,
AV_R: GAAGTAGTCCCAGAAGCCTTTCC, [FAM-AGCGTTTTGGGC-
CAC-NFQ]; ABI systems). APOC3 1100C >T (rs4520): C3_F:
GCCTCCCTTCTCAGCTTCAT, C3_R: CATCCTTGGCGGTCTTGGT,
[FAM-CTTCATGTAACCCTGC-NFQ] and
APOC3 −482C>T (rs2854117): C3_F: AGAGCTCAGCCCTGTAACCA,
C3_R: GGGCTTCTTCAGACTTGAGAACAA, [FAM-ACAGAA-
GACCGGGCAT-NFQ]. The probes were labelled at the 5′ end with 6-
carboxyfluorescein (FAM) and at the 3′ end with a Taqman probe and a non-
fluorescent quencher. Thermal cycling was performed as follows: 50 °C for
2 min, 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C
for 1 min.
2.2. Statistical analysis
Analysis was performed using Stata version 8.2 (Statacorp, Texas). The
number of genotypes for each SNP differed slightly because of random
dropouts. Data from the combined T2D studies, UDACS and EDSC, were
available for the APOA5 −1131T>C genotype on 912 EW, 594 IA and 162 AC
individuals, for the S19W genotype on 908 EW, 590 IA and 161 AC individuals
and on 2348 EW healthy middle-aged men (previously reported in [13]) for the
−1131T>C and 2286 EWs for the S19W genotype, respectively. For the
−482C>T genotype, data were available on 903 EW, 583 IA and 160 ACFigure 1. (a–d) TG levels (adjusted for age, gender, centre and use of lipid lowering m
(NPHSII) showing the percentage effect of rare allele carriers compared to common a
deviation.individuals, on 900 EW, 582 IA and 156 AC individuals for the 1100C>T
genotype, for whom Taqman analysis was successful. For comparison
previously reported APOC3 −482C>T (n=2218) and 1100C>T (n=2373)
genotype data from healthy EWs were used [8].
Results are presented as mean±standard deviation, and for data that was not
normally distributed as the geometric mean±approximate standard deviation or
median (interquartile range), as indicated in the results. Deviations from Hardy–
Weinberg equilibrium were considered using chi-squared test. Allele frequencies
are shownwith the 95% confidence interval. Analysis of variance (ANOVA) was
used to assess the association between genotypes and baseline characteristics on
normally distributed data, or after appropriate transformation (log or square root).
For lipid levels by genotype, means were adjusted for age, gender, centre and use
of lipid loweringmedication using regression estimates of the effects. Analysis of
covariance adjusts for confounding by continuous variables, and was used to
adjust the P values in Figures 1 and 2 for variables including age.
Haplotype analysis was conducted using THESIAS [32]. In all cases, those
carrying one or two of the rare alleles were combined and a P value of less than
0.05 was considered statistically significant. No adjustment was made for
multiple comparisons and results should be interpreted in light of the number of
comparisons made.
3. Results
To obtain maximal power, T2D subjects recruited over the
same period of time from two London hospitals, University
College Hospital (UDACS) and Ealing Hospital (EDSC), were
combined. The overall characteristics of these study groups are
very similar [33] and representative of T2D patients, with theedication) by APOA5 and APOC3 genotypes in EWs, IAs, ACs and healthy EWs
llele homozygotes. Data is presented as geometric means±approximate standard
Figure 2. (a–d) HDL levels (adjusted for age, gender, centre and use of lipid lowering medication) by APOA5 and APOC3 genotypes in EWs, IAs, ACs and healthy
EWs (NPHSII) showing the percentage effect of rare allele carriers compared to common allele homozygotes. Data is presented as geometric means± approximate
standard deviation.
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factors in subjects from the different ethnic groups. Baseline
characteristics for EWs, IAs and ACs with T2D participating
in UDACS and EDSC and healthy EWs (NPHSII) are
shown in Table 1. EWs were older at recruitment than IAs
or ACs, and compared to IAs, EWs were significantly older
at the onset of T2D (P<0.001). ACs had higher HDL-
cholesterol levels than EWs or IAs, and IAs had the highest
TG-levels among the three ethnic groups.
A total of 1668 subjects with T2D were genotyped for
SNPs in the APOA5 (−1131T>C and S19W) and APOC3
(−482C>T and 1100C>T) genes. There was no significant
heterogeneity in genotype distribution between UDACS
and EDSC for any of the SNPs (all P>0.2, data not
shown).Table 2
Rare allele frequencies (95 % CI) of APOA5 (−1131T>C, S19W) and APOC3 (−482
and healthy EWs (NPHSII)
SNP EWs with T2D
(n=931)
IAs with T2D
(n=610)
ACs with T2D
(n=167)
APOA5 −1131T>C 0.07 (0.06–0.08) 0.18 (0.16–0.21) 0.20 (0.16–0.2
APOA5 S19W 0.06 (0.05–0.07) 0.03 (0.02–0.05) 0.04 (0.02–0.0
APOC3 −482C>T 0.24 (0.22–0.26) 0.44 (0.41–0.46) 0.68 (0.64–0.7
APOC3 1100C>T 0.26 (0.24–0.28) 0.41 (0.38–0.44) 0.34 (0.29–0.33.1. APOA5 and APOC3 genotypes and allele frequencies in
patients with T2D
Genotype distributions of APOA5 −1131T>C and S19W
and APOC3 −482C>Tand 1100C>Twere in Hardy–Weinberg
equilibrium, and the rare allele frequencies are presented in
Table 2.
Rare allele frequencies for the APOA5 and APOC3 SNPs
differed significantly among ethnic groups. While APOA5
−1131T>C was approximately 2.5–3 times more frequent in
IAs and ACs than EWs (P<0.001), the S19W was less common
in IAs compared to EWs (P=0.004). For the APOC3 SNPs,
−482C>T was 1.8–2.8 fold and the 1100C>T 1.6–1.3 fold
more frequent in IAs and ACs than EWs, respectively P value
for all <0.02).C>T, 1100C>T) variants in patients with T2D participating in UDACS, EDSC
NPHSII
(n=2578)
P value
(EWs v IAs)
P value
(ACs v IAs)
P value
(ACs v EWs)
5) 0.06 (0.06–0.07) <0.001 0.46 <0.001
7) 0.06 (0.05–0.07) <0.004 0.52 0.25
3) 0.24 (0.23–0.25) <0.001 <0.001 <0.001
4) 0.22 (0.20–0.23) <0.001 0.02 0.002
Table 3
LD matrices for patients with T2D in the different ethnic groups giving the D’
(95 % CI) and the P value
S19W T1131C C482T
(a) European Whites
S19W –
T1131C 1.00
(0.30–1.00)
P<0.001
–
C482T 0.79
(0.37–0.94)
P<0.001
0.78
(0.68–0.86)
P<0.001
–
C1100T 0.80
(0.68–0.88)
P<0.001
0.71
(0.60–0.80)
P<0.001
0.38
(0.32–0.44)
P<0.001
(b) Indian Asians
S19W –
T1131C 1.00
(0.35–1.00)
P=0.004
–
C482T 0.70
(0.25–0.89)
P<0.001
0.70
(0.60–0.78)
P<0.001
–
C1100T 0.73
(0.37–0.89)
P<0.001
0.71
(0.61–0.79)
P<0.001
0.48
(0.41–0.54)
P<0.001
(c) Afro-Caribbeans
S19W –
T1131C 1.00
(0.22–1.00)
P<0.01
–
C482T 0.39
(0.06–0.71)
P=0.03
0.02
(−0.01–0.22)
P=0.78
–
C1100T 0.42
(0.04–0.86)
P=0.04
0.26
(0.07–0.43)
P=0.002
0.37
(0.23–0.49)
P<0.001
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in EWs with T2D compared to healthy EWs
Previously published data [8,13] from a group of healthy UK
EWs participating in NPHSII are also shown in Table 2 and
used for comparison to EW T2D patients. While there was a
statistically significant difference in the frequency of the
APOC3 1100C>T in T2D [0.26 (0.24–0.28)] compared to
healthy EWs [0.22 (0.20–0.23)] P=0.001, there were no rare
allele frequency differences for any of the other SNPs.
3.3. Triglyceride and HDL levels by APOA5 and APOC3
genotypes
3.3.1. APOA5 −1131T>C and S19W
As shown in Figures 1 and 2, compared to TT individuals,
carriers of the −1131C allele, had higher plasma TG levels in
EWs and ACs but this effect reached statistical significance
only in EWs (+11.9%, P=0.04). HDL levels showed
borderline significance in the EWs (−5.5%, P=0.05). This
compared favourably with the previously reported effect
associated with this SNP in EW healthy men of +11.6%
(P=0.001) in TG levels and −4.9% (P=0.004) on HDL levels
[13]. In ACs, compared to TT individuals, carriers of the
−1131C allele had significantly higher total cholesterol
(+6.7%, P=0.04), but this effect was not seen in any other
group (nor in NPHSII healthy EWs) and may be due to
chance alone.
In T2D there was a tendency for carriers of the 19W allele to
have higher TG levels, compared to 19S homozygotes in all
three ethnic groups (Figure 1). However, this reached statistical
significance in IAs only (+49.5%, P<0.001). Furthermore,
HDL levels in 19W carriers were statistically significantly
lower in IAs (−11.3%, P=0.003) and ACs (−16.7%, P=0.05).
Although not statistically significant, in the EWs with T2D,
19W carriers had 7.3% higher TG and 7.1% lower HDL levels
than 19S homozygotes, which were of similar magnitude to that
previously reported in EW healthy individuals [+11.4% TG
(P=0.002) and −7.4% HDL (P=0.005)] [13].
3.4. APOC3 −482C>T and 1100C>T variants
Neither −482C>T nor 1100C>T genotypes showed
significant effects on lipid parameters in any of the ethnic
groups with T2D (data not shown). By comparison, in NPHSII,
1100T carriers had previously been reported to have signifi-
cantly higher TG levels (+7.6%, P=0.001, Figure 1) [8].
3.5. Association of APOA5 (−1131T>C, S19W) and APOC3
(−482C>T, 1100C>T) variants with parameters of T2D
No consistent associations between genotypes and BMI were
seen in the three ethnic groups. In ACs only, APOC3 1100T
carrier individuals had lower mean (±SE) BMI adjusted for age,
gender, centre and lipid lowering medication, than those
homozygous for the common allele [28.0±4.4 kg/m2 (n=72)
vs. 26.6±3.9 kg/m2 (n=84), P=0.04]. In IAs, individualscarrying either the 19W or the −482T allele, had a longer
duration of diabetes compared to common allele carriers
[10 years (5–16) vs. 12 years (8–17), P=0.04 and 8 years
(4–15) vs. 11 (5–16), P=0.05], respectively. None of the
studied SNPs showed a significant association with age of onset
of diabetes in the three ethnic groups of T2D patients. The
APOA5 −1131T>C and APOC3 1100C>T showed no
significant association with duration of diabetes in EW, IA
and AC patients (all P>0.05, data not shown).
3.6. Linkage disequilibrium and haplotype analysis
The linkage disequilibrium matrices for the four SNPs in the
three ethnic groups are shown in Tables 3a–c. The LDs across
the cluster were very similar in the EWs and IAs. In the ACs this
pattern was different, in that the LD between APOA5
−1131T>C and APOC3 −482C>T was not significant, while
LD between APOA5 S19W and the two APOC3 SNPs was
much weaker than in the other ethnic groups.
Haplotypes were assigned using all four SNPs in the order
APOA5 −1131T>C/APOA5 S19W/ APOC3 −482C>T/
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IAs was 1111, occurring at frequencies of 0.62 (95% CI 0.59–
0.64) and 0.43 (95% CI 0.34–0.46) respectively, the common
haplotype in the ACs was 1121 [0.43 (95% CI 0.36–0.49)]
reflecting the differing LD across the genes. The frequencies of
several of the haplotypes differed significantly among EWs, IAs
and ACs (P<0.0001) (Table 4).
The haplotype effects on the fully adjusted lipid levels were
examined, and statistically significant effects over and above
those seen with the single SNPs were evident (Figure 3).
Haplotype analysis in ACs showed no significant association
with TG levels (data not shown). In EWs alone, compared to the
common haplotype (1111), the haplotype defined by the APOA5
−1131C and both rare APOC3 (−482T, 1100T) alleles (2122),
showed a statistically significant effect on TG levels [mean
2.52 mmol/l (95% CI 1.99–3.20), P=0.007, +40%]. The
haplotype with the APOA5 19W allele, also carried the
APOC3 1100 T (1212) and showed a statistically significant
effect on TG levels in IAs, with mean TG levels of 4.66 mmol/l
[(95% CI 2.89–7.52), P<0.001, +135%] and borderline
statistical significance in EWs with T2D of 2.30 mmol/l [(95%
CI 1.81–2.91), P=0.05, +28%], compared to the common
haplotype. However, haplotype 1112 (i.e. defined by the rare
allele of the 1000T) in both IAs and EWs was having a TG-
lowering effect, contrasted to 1111, thus the TG-raising effect
of haplotype 1212 is likely to be due to the 19W allele. The
haplotypes containing the APOC3 −482T, but not APOA5
−1131C (1121 and 1122), did not show any statistically
significant effects on TG levels.
The haplotypic effects on TG in EWs with T2D were
compared to the NPHSII healthy EWs. The only significantly
difference was seen with haplotype 1112. Compared to
haplotype 1111, it showed a TG-lowering effect in the T2D
[1.43 mmol/l (95% CI 1.16–1.78)] with a TG-raising effect in
the healthy EWs [1.96 mmol/l (95% CI 1.69–2.28),
P=0.01)].
3.7. Odds ratios of APOC3 1100T containing haplotypes in
EWs
Haplotype association was carried out in EW patients with
T2D compared to healthy EWs (NPHSII) and odds ratios are
presented in Figure 4. Comparison of APOC3 1100T containing
haplotypes (1112, 1122, 2122, 1212) vs. all other haplotypesTable 4
Haplotype frequencies (95 % CI) of the common haplotypes occurring in EWs, IAs
T1131C/S19W/
C482T/C1100T
EWs IAs ACs N
1111 0.62 (0.59–0.64) 0.43 (0.34–0.46) 0.10 (0.07–0.13) 0
1121 0.11 (0.01–0.13) 0.13 (0.11–0.15) 0.43 (0.36–0.49) 0
1112 0.08 (0.06–0.09) 0.08 (0.07–0.10) 0.11 (0.07–0.16) 0
1122 0.08 (0.06–0.09) 0.15 (0.13–0.17) 0.11 (0.07–0.15) 0
2122 0.05 (0.04–0.07) 0.14 (0.11–0.16) 0.04 (0.02–0.07) 0
1212 0.05 (0.04–0.06) 0.02 (0.01–0.03) 0.01 (0.00–028) 0
2111 0.01 (0.00–0.02) 0.01 (0.00–0.02) 0.01 (0.00–029) 0(1111, 1121, 2111) showed a significantly higher risk of T2D
[Odds ratio 1.23 (95% CI 1.08–1.41, P=0.002].
4. Discussion
4.1. Association of APOA5 and APOC3 SNPs with lipid levels
Since high TG levels are common in subjects with T2D [34],
our aim was to gain more insight into the effects of APOA5 and
APOC3 variants on lipid parameters and traits commonly seen
in patients with T2D. The results obtained were according to
expectation, with raised (or similar) TG levels for the APOA5
−1131C allele in all ethnic groups. In EWs, −1131C carriers
had 11.9% higher TG levels (P=0.04) and 5.5% lower HDL
levels (P=0.05) than those homozygous for the common allele.
Although the frequency of the −1131C allele was significantly
higher in IAs and ACs, the TG raising effect was smaller and
not statistically significant (elevation of +10% in ACs and no
difference in IAs in C+ vs. TT carriers). By comparison, the size
of the effect on TG-raising and HDL lowering in the EWs with
T2D were similar to those previously reported in healthy
subjects [+11.6% (P=0.001) vs. −4.9% (P=0.004), respec-
tively] [13].
The APOA5 S19W variant has also been shown to display
TG-raising, and to a lesser extent HDL-cholesterol lowering
effects, in healthy subjects [6,7,13,35,36], although not always
consistently [7,13,37–39]. The effect seen here was larger than
expected in IAs with T2D, where carriers of the 19W allele had
49.5% higher TG levels than 19S homozygotes (P<0.001).
HDL levels were statistically significantly lowered in 19W+ in
IA and ACs and of borderline significance in EWs. In EWs and
ACs with T2D, the S19W effect on TG levels was less
pronounced (7.3% and 24.6% of W+ vs. SS carriers,
respectively) and did not reach statistical significance. How-
ever, this effect was of similar magnitude to that seen in healthy
EWs, 11.4% (P=0.002), with a significant reduction of 7.4% of
HDL levels (P=0.005) [13]. Failure of the current study to
detect a consistent significant effect of both APOA5 SNPs on
TG levels in EWs, IAs and ACs may be due to the lack of
power. It was estimated that the combined UDACS and EDSC
studies had a power (at the 5% significance level) of only 11.4%
in IAs and 32% in ACs for the −1131T>C SNP to detect a
0.04–0.14 mmol/l difference in TG levels, respectively and a
power of 31.5% in EWs and 41.2% in ACs for the S19W SNPand ACs with T2D and in healthy EWs (NPHSII)
PHSII P value
EWs T2D v
NPHSII EWs
P value
EWs v IAs
P value
EWs v ACs
P value
IAs v ACs
.62 (0.60–0.64) 0.60 <0.001 <0.001 <0.001
.13 (0.11–0.15) 0.12 0.06 <0.001 <0.001
.06 (0.06–0.07) 0.11 0.40 0.11 0.21
.06 (0.06–0.07) 0.10 <0.001 0.14 0.08
.04 (0.03–0.05) 0.08 <0.001 0.74 <0.001
.05 (0.04–0.05) 0.90 0.002 0.05 0.36
.01 (0.01–0.02) 0.44 0.37 0.65 0.92
Figure 3. Haplotypic effects on adjusted (age, gender, centre and use of lipid lowering medication) TG levels in EWs and ACs with T2D and healthy EWs (NPHSII).
Data is presented as geometric mean for two copies of the haplotype (±CI).
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respectively (differences previously seen in healthy subjects,
[13]. Dallinga-Thie et al. [40], who examined the impact of
these two SNPs in a Dutch cohort of 215 patients with T2D
reported no significant association of either −1131C or 19W
variants with plasma TG levels. However, it is likely that these
results are also due to the lack of power of that study.
For the APOC3 variants, neither of the studied SNPs
(−482C>T and 1100C>T) showed a significant effect on TG
or HDL levels or other studied lipid parameters in these diabetic
cohorts. In the NPHSII study, a TG-raising effect was observed
for the rare allele of APOC3 1100C>T [13], while the
−482C>T showed strong interaction with smoking on TG
levels [8]. We examined the interaction of both APOC3 SNPs
with smoking on lipid parameters but found no significant
interaction in any of the ethnic groups (data not shown). Again,
this may be because of the lack of power and the lower
prevalence of current smokers in these groups (EWs 16.8%; IAs
4.5%; ACs 7.8% compared to 26.8% in NPHSII).
Recent studies have shown that rare alleles of the two
APOA5 SNPs, S19W and −1131T>C, while both having TG-
raising effects, have different effects on apoAV mass. Carriers
of the 19W allele have significantly higher apoAV levels
compared to 19S homozygotes [41] and in NPHSII weFigure 4. Odds ratios (95 % CI) for T2D contrasting EWs with T2D with healthy E
1100C>T) genotypes. Frequencies for the different haplotypes (healthy EWs v. EWs
0.08), 2122 (0.05; 0.05), 1212 (0.04; 0.05).confirmed this association [42]. However, while Vaessen et al.
[41] reported that the −1131C carriers have significantly lower
apoAV mass compared to −1131T homozygotes, in NPHSII,
there was no difference in apoAV levels in −1131TT and
−1131C carriers [42]. In vitro analysis of −1131T>C suggests
that it is not a functional change [15], and therefore would not
be expected to be associated with differences in plasma apoAV
levels. Differences in apoCIII levels have been associated with
the SstI SNP (3238C>G) in the 3′UTR of APOC3, with S2
(3238G) carriers having significantly higher levels than S1
(3238C) homozygotes, however the promoter SNPs −482C>T
and −455C>T showed no association with differences in
apoCIII levels [43].
4.2. Haplotype analysis
Haplotype effects on adjusted lipid parameters show that the
haplotype featuring the APOA5 −1131C and both rare APOC3
alleles (2122) compared to the common haplotype, had
statistically significant effects on TG levels in EWs with T2D
only. The APOA5 −1131T>C has been reported to show strong
LD with both APOC3 variants [12,13] and this was confirmed
in EWs and IAs with T2D, D´=0.78 and D´=0.70, respectively
(P<0.001 for both). This haplotype occurs at a frequency of 5%Ws (NPHSII) based on APOA5 (−1131T>C, S19W) and APOC3 (−482C>T,
with T2D) are: 1111 (0.62; 0.62), 1121 (013; 011), 1112 (0.06; 0.08), 1122 (0.06;
362 B. Dorfmeister et al. / Biochimica et Biophysica Acta 1772 (2007) 355–363in EWs and 14% in IAs, yet had no effect on TG levels in IAs.
In vitro experiments suggest that the −1131T>C is unlikely to
be functional [15] its association with TG levels reflect the
strong LD with −482C>T, which has been reported to be
functional [16]. However, a pertinent outcome of this analysis is
that haplotypes defined by the rare allele of the APOC3 −482T
on a wildtype background or with 1100C>T (1121 and 1122)
show no elevation of TG levels compared to haplotype 1111,
suggesting that despite their strong LD, APOA5 −1131T>C
and APOC3 −482C>T are acting independently through
different molecular mechanisms.
The common haplotype defined by rare alleles of APOA5
19W occurred on the same haplotype as APOC3 1100T (1212)
at a frequency of 20% in IAs and 5% in EWs. In the IAs it was
associated with 135% higher TG levels compared to common
haplotype which was highly statistically significant (P<0.001).
This haplotype also showed TG-raising in EWs of 28%
(P=0.05). However the haplotype defined by 1100T, either
alone or with −482T, either showed TG-lowering or TG-neutral
effects. Thus in haplotype analysis, the 19W is having a very
strong effect. S19W has been shown to be functional and affect
signal peptide function [15].
Despite the inability to detect an effect of the APOC3
1100C>T on TG levels in patients with T2D, there was a
significantly higher frequency of the 1100T allele in EWs with
T2D compared to healthy EWs [NPHSII, (P<0.001)], suggest-
ing that variation in APOC3, as defined by this SNP, could be
associated with increased risk of T2D.
It is not possible to analyse the data using survival analysis,
since these data are not available for patients with T2D. The
odds ratios for developing T2D were obtained from a logistic
regression model contrasting EWs with T2D with healthy EWs
(NPHSII). In this analysis we compared all haplotypes
containing APOC3 1100T (1112, 1122, 2122 and 1212) with
the haplotype defined by the common alleles (i.e. 1111). 1100T-
containing haplotypes had a significantly higher OR than
haplotype 1111 (P=0.002). These data are presented in Figure
4. Since 1100T is associated with TG-lowering in EWs with
T2D this suggests that this effect on T2D risk is independent of
effects on TG levels.
It is of interest that the TG-raising effect associated with the
19W was about four-fold larger in IAs with T2D than in healthy
individuals [13]. This effect could be due to chance but, if
confirmed in other studies, it suggests that either lifestyle-
specific factors or ethnic-specific genetic factors might be
interacting with the APOA5 SNP in the determination of
triglyceride metabolism.
There are several limitations of this study. Firstly, we do
not have a sample of healthy IAs and ACs to use as
comparison for the T2Ds. Secondly, blood samples were non-
fasting and this raises the question as to the utility of non-
fasting TG measures for risk evaluation, although plausibly
such measures might better reflect habitual levels and levels of
atherogenic postprandial lipoproteins. However, any variabil-
ity caused by the differences in degree in fasting must be
random and any added effect of such random variation in TG
levels would only add ‘noise’ to the risk estimate and isunlikely to confound it. Finally, we do not have any fasting
glucose or insulin levels to further strengthen the observed
association of APOC3 1100C>T with T2D.
Thus the conclusion from our study is that despite the
APOA5 SNPs having strong but variable effects on TG levels in
EWs and IAs, they do not appear to affect age of onset of
diabetes or BMI. The possibility that diabetic status may be
masking any effect of the studied genotypes cannot however be
excluded and gene–gene and gene–environment interactions
may differ between populations and should also be taken into
account for further studies.
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